Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHABET Study
NCT05063786Phase 3Terminated
- Sponsor
- GEICAM
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of alpelisib in breast cancer, sponsored by GEICAM. Started Sep 2021; status: terminated.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05063786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063786.